Bevacizumab is currently marketed for anti-tumor indications.
Notes on verification
Confirmed by EMA and FDA regulatory documents, manufacturer (Roche) product information, and recent financial disclosures showing ongoing marketing for oncology indications.
Sources
- Procedura di infrazione da parte dell'Autorità Antitrust (epicentro.iss.it)
- https://www.ema.europa.eu/en/medicines/human/EPAR/avastin (ema.europa.eu)
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdf (accessdata.fda.gov)
- https://www.avastin.com/hcp.html (avastin.com)
- https://www.roche.com/investors/updates/inv-update-2025-10-23 (roche.com)
- https://www.roche.com/solutions/pharma/productid-d263d2d3-708f-4fbd-87da-23364b2958f6 (roche.com)
- https://www.drugs.com/history/avastin.html (drugs.com)